Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THERAPEUTIC EFFICACY OF THE TOPOISOMERASE-I INHIBITOR PIPERIDINO]-1-PIPERIDINO)-CARBONYLOXY-CAMPTOTHECIN AGAINST PEDIATRIC AND ADULT CENTRAL-NERVOUS-SYSTEM TUMOR XENOGRAFTS
Autore:
HARE CB; ELION GB; HOUGHTON PJ; HOUGHTON JA; MARCELLI SL; KEIR S; BIGNER DD; FRIEDMAN HS;
Indirizzi:
DUKE UNIV,MED CTR,DEPT PEDIAT DURHAM NC 27710 DUKE UNIV,MED CTR,DEPT PEDIAT DURHAM NC 27710 DUKE UNIV,MED CTR,DEPT PHARMACOL DURHAM NC 27710 ST JUDE CHILDRENS HOSP,DEPT MOL PHARMACOL MEMPHIS TN 38101 DUKE UNIV,MED CTR,PREUSS LAB BRAIN TUMOR RES DURHAM NC 27710
Titolo Testata:
Cancer chemotherapy and pharmacology
fascicolo: 3, volume: 39, anno: 1997,
pagine: 187 - 191
SICI:
0344-5704(1997)39:3<187:TEOTTI>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
ATHYMIC NUDE-MICE; HUMAN MEDULLOBLASTOMA; RHABDOMYOSARCOMA XENOGRAFT; EXPERIMENTAL CHEMOTHERAPY; AGENTS;
Keywords:
CPT-11; TOPOISOMERASE; CNS TUMORS; XENOGRAFT; CAMPTOTHECIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
15
Recensione:
Indirizzi per estratti:
Citazione:
C.B. Hare et al., "THERAPEUTIC EFFICACY OF THE TOPOISOMERASE-I INHIBITOR PIPERIDINO]-1-PIPERIDINO)-CARBONYLOXY-CAMPTOTHECIN AGAINST PEDIATRIC AND ADULT CENTRAL-NERVOUS-SYSTEM TUMOR XENOGRAFTS", Cancer chemotherapy and pharmacology, 39(3), 1997, pp. 187-191

Abstract

Therapy of patients with malignant central nervous system tumors is frequently unsuccessful, reflecting limitations of current surgical, radiotherapeutic, and pharmacotherapeutic treatments. The camptothecin derivative irinotecan (CPT-11) has been shown to possess antitumor activity in phase II trials for patients with carcinoma of the lung, cervix, ovary, colon, or rectum and for patients with non-Hodgkin's lymphoma. The current study was designed to test the efficacy of the drug against a panel of human tumor xenografts derived from adult and pediatric central nervous system malignancies. Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG,D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines withdemonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide(TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice. In replicate experiments, CPT-11 was given at a dosage of 40 mg/kg per dose via intraperitoneal injection in 10% dimethylsulfoxide on days 1-5 and 8-12, which is the dosage lethal to 10% of treated animals. CPT-11 produced statistically significant (P < 0.001) growth delays in all subcutaneous xenografts tested, including those resistant to busulfan, cyclophosphamide, procarbazine, and melphalan, with growth delays ranging from 21.3 days in D487 Med to 90 + days in several tumor lines. Further, tumor regression was evident in every treated animal bearing a subcutaneous tumor, with some xenografts yielding complete tumor regression. Statistically significant (P < 0.001) increases in survival were demonstrated in the two intracranial xenografts - D341 EP (73.0% increase) and D-456 MG (114.2% increase) - treated with CPT-11. These studiesdemonstrate that, of over 40 drugs evaluated in this laboratory, CPT-11 is the most active against central nervous system xenografts and should be advanced to clinical trial as soon as possible.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 11:57:42